Results 151 to 160 of about 22,142 (188)

Real-world treatment patterns and outcomes in chronic lymphocytic leukemia: a multicenter retrospective study in Greece. [PDF]

Ann Hematol
Koumpis E, Minga E, Talimtzi P, Angelopoulou M, Chatzileontiadou S, Dimou M, Besikli-Dimou S, Efstathopoulou M, Gogos D, Hatjiharissi E, Hatzimichael E, Iskas M, Konstantinou E, Kotsianidis I, Machairas A, Mpalaoura E, Mpanti A, Panagiotidis P, Pangalis G, Papadopoulos I, Papaioannou M, Siakantaris M, Stavroyianni N, Vassilakopoulos T, Vrachiolias G, Stamatopoulos K, Chatzidimitriou A, Chatzikonstantinou T.   +27 more
europepmc   +1 more source

Cost-effectiveness analysis of ibrutinib plus venetoclax for relapsed or refractory mantle cell lymphoma in China and the United States. [PDF]

Front Public Health
He J, Liu X, Yang Q.
europepmc   +1 more source

Case Report and Retrospective Review of Acanthamoeba Encephalitis and Chronic Lymphocytic Leukemia, United States. [PDF]

Emerg Infect Dis
Persico M, Haston JC, Imada E, Kasten J, Pimentel C, Collins JM.   +5 more
europepmc   +1 more source

Chronic lymphocytic leukemia management in India: balancing evidence, access, and affordability in clinical practice. [PDF]

Front Oncol
Sahni S, Rani L, Gupta R, Gogia A.
europepmc   +1 more source

First-Line Bruton's Tyrosine Kinase Inhibitor-Based Regimens for Mantle Cell Lymphoma. [PDF]

Curr Oncol
Puckrin R, Villa D, Fleury I, Larouche JF, Kuruvilla J.   +4 more
europepmc   +1 more source

Optic nerve infiltration in chronic lymphocytic leukemia treated with acalabrutinib monotherapy: A case report. [PDF]

Am J Ophthalmol Case Rep
Shakarchi FF, Chacko JA, Chacko JG, Govindarajan R, Zent CS, Uwaydat SH.   +5 more
europepmc   +1 more source

Marginal zone lymphoma is associated with dysregulated T-cell immunity that is not altered by ibrutinib-venetoclax treatment. [PDF]

Blood Neoplasia
Davis JE, Le LHH, Ludford-Menting M, Holzwart N, Handunnetti SM, Tam CS, Anderson MA, Ritchie DS, Koldej RM.   +8 more
europepmc   +1 more source

IGLV3-21^R110 and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL. [PDF]

Hemasphere
Yosifov DY, Robrecht S, Giza A, Maity PC, Riecke A, Schneider C, Jebaraj BMC, Dheenadayalan RP, Jumaa H, Young M, Kumar M, Müller L, Vehling-Kaiser U, Eckart M, Freier W, Schöttker B, Gaska T, Reiser M, Fink AM, Fischer K, Eichhorst B, Hallek M, Langerbeins P, Tausch E, Stilgenbauer S.   +24 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Ibrutinib

Reactions Weekly, 2018
Abnormal B-cell receptor (BCR) signalling is a key mechanism of disease progression in B-cell malignancy. Bruton's tyrosine kinase (BTK) has a pivotal role in BCR signalling. Ibrutinib (PCI-32765) is a small molecule which serves as a covalent irreversible inhibitor of BTK. It is characterized by high selectivity for BTK and high potency.
Andriani, Charalambous, Mark-Alexander, Schwarzbich, Mathias, Witzens-Harig   +2 more
  +9 more sources

Ibrutinib

Reactions Weekly, 2021
  +10 more sources